Article

Bone Mineral Density in Lymphangioleiomyomatosis

Pulmonary-Critical Care Medicine Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Building 10, Room 6D05, MSC 1590, Bethesda, MD 20892-1590, USA.
American Journal of Respiratory and Critical Care Medicine (Impact Factor: 13). 01/2005; 171(1):61-7. DOI: 10.1164/rccm.200406-701OC
Source: PubMed

ABSTRACT

Estrogen deficiency and pulmonary diseases are associated with bone mineral density (BMD) loss. Lymphangioleiomyomatosis (LAM), a disorder affecting women that is characterized by cystic lung lesions, is frequently treated with antiestrogen therapy, i.e., progesterone and/or oophorectomy. Therefore, we evaluated BMD yearly in 211 LAM patients to determine the prevalence of BMD abnormalities, whether antiestrogen therapy decreased BMD, and if treatment with bisphosphonates prevented bone loss. Abnormal BMD was found in 70% of the patients and correlated with severity of lung disease and age. Greater severity of lung disease, menopause, and oophorectomy were associated with greater decline in BMD. After adjusting for differences in initial lung function and BMD, we found similar rates of BMD decline in progesterone-treated (n = 122) and untreated patients (n = 89). After similar adjustments, we found that bisphosphonate-treated patients (n = 98) had lower rates of decline in lumbar spine BMD (-0.004 +/- 0.003 vs. -0.015 +/- 0.003 gm/cm(2), p = 0.036) and T-scores (-0.050 +/- 0.041 vs. -0.191 +/- 0.041, p < 0.001) than untreated patients (n = 113). We conclude that abnormal BMD was frequent in LAM. Progesterone therapy was not associated with changes in BMD; bisphosphonate therapy was associated with lower rates of bone loss. We recommend systematic evaluation of BMD and early treatment with bisphosphonates for patients with LAM.

Full-text preview

Available from: 171.66.122.149
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Vitamin D deficiency is increasingly being recognized as a prevalent problem in the general population. Patients with chronic lung diseases such as asthma, cystic fibrosis, chronic obstructive lung disease and interstitial pneumonia appear to be at increased risk for vitamin D deficiency for reasons that are not clear. Several studies indicate that vitamin D possesses a range of anti-inflammatory properties and may be involved in processes other than the previously believed functions of calcium and phosphate homeostasis. Various cytokines, cellular elements, oxidative stress and protease/antiprotease levels appear to affect lung fibroproliferation, remodelling and function, which may be influenced by vitamin D levels. Chronic lung diseases such as asthma and chronic obstructive lung disease have also been linked to vitamin D on a genetic basis. This immune and genetic influence of vitamin D may influence the pathogenesis of chronic lung diseases. A recent observational study notes a significant association between vitamin D deficiency and decreased pulmonary function tests in a large ambulatory population. The present review will examine the current literature regarding vitamin D deficiency, its prevalence in patients with chronic lung disease, vitamin D anti-inflammatory properties and the role of vitamin D in pulmonary function.
    Preview · Article · Jun 2009 · Canadian respiratory journal: journal of the Canadian Thoracic Society
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Osteoporosis (OP) is an increasingly important public health problem as our population ages [1]. The major threats of the disease are fractures, which represent a considerable medical, social and economic burden. Although partially preventable with adequate treatment, fractures related to OP are still common. It appears that OP is a particular problem in patients with chronic respiratory failure of various origins, which must be taken into account during their management. This problem is of particular importance in candidates for lung transplantation [2, 3]. The aim of this chapter is to discuss the prevalence of the disease, the mechanisms of pathogenesis, and criteria for diagnosis and recommendations for treatment in patients with end-stage lung disease. What is osteoporosis? OP is a systemic disease of skeletal bones, leading to increased fragility and an increased risk for fractures. It takes much less stress to cause a fracture in an osteoporotic bone than in a normal bone. The term ''osteoporosis'' means spongy, which describes the appearance of broken osteoporotic bones, when looking at the surface of the fragments. The clinical significance of OP is associated with a higher risk of fractures, which significantly worsens vital prognosis and quality of life. OP is classified as either primary (post-menopausal or age-related) or secondary, the latter being related to chronic diseases, drug therapy or lifestyle [4]. In post-menopausal OP, oestrogen deficiency causes a loss of bone tissue owing to an increased metabolic turnover, characterised by an increase in the number and depth of remodelling sites. Areas with large amounts of trabecular bone are most affected; therefore, wrist and vertebral fractures tend to be predominant. Age-related OP occurs in males and females .75 yrs of age and is due to decrease in calcium absorption, vitamin D levels, osteoblast function and life span, and genital hormone production. Together, post-menopausal and senile OP represent 85% of all the variants. Cortical and trabecular bone are both affected, leading to increases in all types of fractures, in particular hip fractures. However, during the past decade, secondary OP due to various pathogenetic pathways is growing in clinical practice [5].
    Full-text · Article ·
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Lymphangioleiomyomatosis (LAM) is a progressive and usually fatal interstitial lung disease characterized by an abnormal smooth-muscle proliferation in the lung and axial lymphatics. It affects almost exclusively young women of childbearing age. The presenting features most commonly include dyspnea, symptoms of pneumothorax and cough. Less commonly patients can present with chest pain, pleural or pericardial effusion and lymphedema. Our patient, a 41-year-old woman, complained mainly of fatigue that had lasted for 2 months and finally became febrile and dispneic, especially when lying down. Pulmonary diagnostic procedures revealed several multicystic destruction of lung parenchyma. There was also respiratory insufficiency with O2 saturation of 87% and lung diffusion capacity reduced to 48%. The retroperitoneum was filled with neoplastic mass as shown on an abdominal CT scan. Pathohistologic analysis of retroperitoneal mass together with the radiologic finding of the lungs correlated with the diagnosis of LAM. The patient was prescribed corticosteroid therapy, which led to rapid clinical improvement. After making a definite diagnosis, the patient was recommended further treatment with medroxyprogesterone. This case shows that LAM, although rare, can present a diagnostic problem to clinicians and should always be considered as one of the diagnostic possibilities in young women with nonspecific pulmonary symptoms.
    Full-text · Article · Feb 2004 · Acta medica Croatica: c̆asopis Hravatske akademije medicinskih znanosti
Show more